Thermo Fisher Scientific (TMO)

Total Liabilities

$59.47B

Quarterly · Period ending: · USD

TMO logo

TMO Total Liabilities

Latest reported$59.47B
TMO Quarterly Total Liabilities ($120.10M → $59.47B)
High-resolution chart · PNG

TMO total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Thermo Fisher Scientific Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
59,466,000,000
60,488,000,000
61,220,000,000
56,807,000,000
51,866,000,000
50,628,000,000
49,556,000,000
47,650,000,000
51,265,000,000
50,963,000,000
51,472,000,000
51,884,000,000
51,593,000,000
50,190,000,000
52,225,000,000
53,006,000,000
46,809,000,000
48,108,000,000
51,616,000,000
54,146,000,000
34,890,000,000
30,844,000,000
30,873,000,000
34,535,000,000
32,237,000,000
31,718,000,000
30,129,000,000
28,706,000,000
27,374,000,000
29,241,000,000
27,903,000,000
28,646,000,000
28,188,000,000
28,958,000,000
30,457,000,000
31,256,000,000
31,283,500,000
24,122,100,000
24,418,400,000
24,368,000,000
26,352,100,000
20,989,500,000
22,028,300,000
19,484,100,000
20,296,900,000
21,094,600,000
21,942,500,000
22,304,000,000
22,180,200,000
23,654,800,000
25,703,100,000
15,007,300,000
11,835,200,000
11,826,700,000
11,811,200,000
11,979,900,000
12,287,500,000
11,266,900,000
11,533,700,000
11,795,600,000
11,795,600,000
8,408,100,000
8,175,900,000
5,988,400,000
6,140,400,000
5,935,800,000
6,144,600,000
6,194,100,000
6,019,100,000
6,079,200,000
6,040,600,000
6,163,400,000
6,463,900,000
6,611,000,000
6,712,100,000
6,719,100,000
6,729,500,000
6,740,300,000
6,939,200,000
7,350,411,000
1,383,196,000
1,439,197,000
1,366,606,000
1,458,257,000
1,384,633,000
1,441,320,000
877,770,000
911,175,000
938,157,000
1,041,532,000
1,027,644,000
1,006,163,000
887,316,000
1,092,773,000
1,328,525,000
1,613,739,000
1,710,896,000
1,783,034,000
1,875,761,000
1,910,027,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.